The effect of antihypertensive therapy and CPAP therapy on inflammatory and endothelial dysfunction markers levels in patients with severe obstructive sleep apnea syndrome in association with arterial hypertension

Objective. To evaluate the effect of antihypertensive therapy (AHT) and CPAP therapy on inflammatory and endothelial dysfunction markers levels in patients with severe obstructive sleep apnea (OSA) syndrome in association with arterial hypertension (AH). Materials and methods. The study included 43 male patients with severe OSA syndrome (Apnea-Hypopnea Index 52.4 [46.1; 58.6]) and AH (systolic blood pressure 144.0 [142.0; 156.0] mm Hg, diastolic blood pressure 90.9 [88.3; 93.5] mm Hg). Treatment with angiotensin-converting enzyme inhibitors, calcium antagonists, and thiazide-like diuretics was performed till target BP level measured with Korotkoff method was achieved. The patients who had reached target BP level (BP≤140/90 mm Hg) were randomized into two groups: group 1 included 23 patients who continued taking the AHT, group 2 included 22 patients who continued taking the AHT to which CPAP therapy was added. Peripheral blood lymphocyte immunophenotyping, cytokine panel test (IL-1β, IL-6, tumor necrosis factor a, IL-2Ra, sCD40L), adhesion molecule analysis (ICAM-1, VCAM-1), thromboxane B2, 6-keto-prostaglandin F1 alpha (6-keto-PGF1a), and endothelin-1 levels in blood serum were evaluated at admission, after target BP level achievement (2nd visit) and after 3 months of AHT or AHT+CPAP therapy (3rd visit). Flow-mediated dilation of brachial artery was assessed using reactive hyperemia test by D.Celermajer. Results. Against the background of combined AHT the target BP level was achieved by 95% of patients. After target BP level achievement a significant decrease of IL-1β -0.16 [-0.5; 0], p=0.000 level and number of CD50+ cells (lymphocytes with inter-cellular adhesion molecule ICAM-3) from 2158.5 [1884.7; 2432.3] to 1949.6 [1740.9; 2158.3], p=0.050 were observed in patients with severe OSA associated with AH. There were no significant changes in vascular endothelial function observed in patients taking only AHT. Significant decrease of fibrinogen (-0.3 [-0.4; -0.1], p=0.002) and homocystein (-2.03 [-3.8; -0.2], p=0.03) levels was observed in patients taking both AHT and CPAP therapy. Conclusion. The combination of AHT and CPAP therapy in patients with severe OSA and AH not only allows reaching the target BP level but also leads to inflammatory and endothelial dysfunction markers levels decrease.

CPAP, arterial hypertension, antihypertensive therapy, obstructive sleep apnea syndrome, inflammatory markers, endothelial dysfunction

1. Arnardottir E.S, Bjornsdottir E, Olafsdottir K.A et al. Obstructive sleep apnoea in the general population: highly prevalent but minimal symptoms. Eur Respir J 2016; 47: 194-202.

2. Heinzer R, Vat S, Marques-Vidal P et al. Prevalence of sleep - disordered breathing in the general population: the Hypno Laus study. Lancet Respir Med 2015; 3: 310-8.

3. Parati G, Lombardi C, Hedner J et al. Recommendations for the management of patients with obstructive sleep apnoea and hypertension. Eur Respir J 2013; 41: 523-38.

4. Seif F, Patel S.R, Walia H.K et al. Obstructive sleep apnea and diurnal nondipping hemodynamic indices in patients at increased cardiovascular risk. J Hypertens 2014; 32: 267-75.

5. Cutler J.A, Sorlie P.D, Wolz M et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52: 818-27.

6. Marin J.M, Carrizo S.J, Vicente E et al. Long - term cardiovascular outcomes in men with obstructive sleep apnoea - hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-53.

7. Yaggi H.K, Concato J, Kernan W.N et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353: 2034-41.

8. Narkiewicz K, van de Borne P.J, Montano N et al. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 1998; 97: 943-5.

9. Carlson J.T, Hedner J, Elam M et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993; 103: 1763-8.

10. Imadojemu V.A, Gleeson K, Quraishi S.A et al. Impaired vasodilator responses in obstructive sleep apnea are improved with continuous positive airway pressure therapy. Am J Respir Crit Care Med 2002; 165: 950-3.

11. Kato M, Roberts-Thomson P, Phillips B.G et al. Impairment of endothelium - dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000; 102: 2607-10.

12. Shamsuzzaman A.S, Gersh B.J, Somers V.K. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290: 1906-14.

13. Jelic S, Padeletti M, Kawut S.M et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 2008; 117: 2270-8.

14. Libby Р. Inflammation in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2012; 32: 2045-51.

15. Lavie L. Intermittent hypoxia: the culprit of oxidative stress, vascular inflammation and dyslipidemia in obstructive sleep apnea. Expert Rev Resp Med 2008; 2: 75-84.

16. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.

17. Meigs J.B, Larson M.G, Fox C.S et al. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 2007; 30: 2529-35.

18. Sung K.C et al. High sensitivity C - reactive protein as an independent risk factor for esse.

19. Yudkin J.S, Kumari M, Humphries S.E, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-14.

20. Балахонова Т.В. Ультразвуковое исследование артерий у пациентов с сердечно - сосудистыми заболеваниями. Автореф. дис. … д - ра мед. наук. М., 2002.

21. Chin K, Ohi M, Kita H et al. Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1996; 153 (6 Pt. 1): 1972-6.

22. Wu S.Q, Liao Q.C, Xu X.X et al. Effect of CPAP therapy on C-reactive protein and cognitive impairment in patients with obstructive sleep apnea hypopnea syndrome. Sleep Breath 2016.

23. Sun L, Chen R, Wang J et al. Association between inflammation and cognitive function and effects of continuous positive airway pressure treatment in obstructive sleep apnea hypopnea syndrome. Zhonghua Yi Xue Za Zhi 2014; 94 (44): 3483-7.

24. Маркин А.В., Цеймах И.Я., Нагайцев В.М. Оценка выраженности системного воспаления у пациентов с синдромом обструктивного апноэ сна. Медицина и образование в Сибири. 2013; 6.

25. Libby P. Inflammation in atherosclerosis. Nature 2002; 420 (6917): 868-74.

26. Diefenbach K, Kretschmer K, Bauer S et al. Endothelin-1 Gene Variant Lys198. Asn and Plasma Endothelin Level in Obstructive Sleep Apnea. Cardiology 2009; 112: 62-8.

27. Mejza F, Kania A, Nastalek P et al. Systemic prostacyclin and thromboxane production in obstructive sleep apnea. Adv Med Sci 2016; 61 (1): 154-9. DOI: 10.1016/j.advms.2015.12.001.

28. Simpson P.J, Hoyos C.M, Celermajer D et al. Effects of continuous positive airway pressure on endothelial function and circulating progenitor cells in obstructive sleep apnoea: a randomised sham - controlled study. Int J Cardiol 2013; 168 (3): 2042-8. DOI: 10.1016/j.ijcard.2013.01.166.

29. Monneret D, Tamisier R, Ducros V et al. Glucose tolerance and cardiovascular risk biomarkers in non - diabetic non - obese obstructive sleep apnea patients: Effects of long - term continuous positive airway pressure. Respir Med 2016; 112: 119-25. DOI: 10.1016/j.rmed.2016.01.015.

30. Steiropoulos P, Tsara V, Nena E et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea - hypopnea syndrome. Chest 2007; 132 (3): 843-51.

31. Hijmering M.L, Stroes E.S, Olijhoek J et al. Sympathetic activation markedly reduces endothelium - dependent, flow - mediated vasodilation. J Am Coll Cardiol 2002; 39 (4): 683-8.

32. Thijssen D.H.J, Atkinson C.L, Ono K et al. Sympathetic nervous system activation, arterial shear rate, and flow - mediated dilation. J Appl Physiol Pub 2014; 116 (10): 1300-7. DOI: 10.1152/japplphysiol.00110.2014.